Disordered epigenetic regulation in MLL-related leukemia

[1]  S. Armstrong,et al.  Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. , 2012, Trends in immunology.

[2]  M. Caligiuri,et al.  Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. , 2012, Blood.

[3]  J. Licht,et al.  Emerging epigenetic targets and therapies in cancer medicine. , 2012, Cancer discovery.

[4]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[5]  J. Hess,et al.  The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.

[6]  D. Tenen,et al.  The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. , 2011, Blood.

[7]  S. Armstrong,et al.  A role for DOT1L in MLL-rearranged leukemias. , 2011, Epigenomics.

[8]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[9]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[10]  Yi Zhang,et al.  Essential role of DOT1L in maintaining normal adult hematopoiesis , 2011, Cell Research.

[11]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[12]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[13]  Dafydd G. Thomas,et al.  Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. , 2011, Blood.

[14]  D. Liang,et al.  Expression of HOXB genes is significantly different in acute myeloid leukemia with a partial tandem duplication of MLL vs. a MLL translocation: a cross-laboratory study. , 2011, Cancer genetics.

[15]  N. Zeleznik-Le,et al.  Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. , 2010, Cancer research.

[16]  J. Hess,et al.  PAFc, a Key Player in MLL-rearranged Leukemogenesis , 2010, Oncotarget.

[17]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[18]  C. Allis,et al.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.

[19]  Thomas A. Milne,et al.  Pro Isomerization in MLL1 PHD3-Bromo Cassette Connects H3K4me Readout to CyP33 and HDAC-Mediated Repression , 2010, Cell.

[20]  Jiaying Tan,et al.  The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.

[21]  M. Cosgrove,et al.  Mixed lineage leukemia: a structure–function perspective of the MLL1 protein , 2010, The FEBS journal.

[22]  A. Gewirtz,et al.  c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. , 2010, The Journal of clinical investigation.

[23]  K. Ozato,et al.  Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. , 2009, Molecular biology of the cell.

[24]  M. Liedtke,et al.  Therapeutic targeting of MLL. , 2009, Blood.

[25]  R. Roeder,et al.  A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 , 2009, Proceedings of the National Academy of Sciences.

[26]  M. Krzywinski,et al.  New insights to the MLL recombinome of acute leukemias , 2009, Leukemia.

[27]  M. Caligiuri,et al.  DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. , 2008, Blood.

[28]  N. Zeleznik-Le,et al.  Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. , 2008, Cancer research.

[29]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[30]  D. Kioussis,et al.  Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. , 2007, Cell stem cell.

[31]  Ruedi Aebersold,et al.  Activator-mediated recruitment of the MLL2 methyltransferase complex to the beta-globin locus. , 2007, Molecular cell.

[32]  Winship Herr,et al.  E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. , 2007, Molecular cell.

[33]  Aarthi Narayanan,et al.  The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection , 2007, Proceedings of the National Academy of Sciences.

[34]  M. Caligiuri,et al.  Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. , 2006, The Journal of clinical investigation.

[35]  P. Aplan,et al.  Chromosomal translocations involving the MLL gene: molecular mechanisms. , 2006, DNA repair.

[36]  A. Shilatifard,et al.  Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes , 2006, Nature Structural &Molecular Biology.

[37]  B. Peterlin,et al.  Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.

[38]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[39]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[40]  M. Caligiuri,et al.  The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. , 2005, Blood.

[41]  Thomas A. Milne,et al.  Physical Association and Coordinate Function of the H3 K4 Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF , 2005, Cell.

[42]  Thomas A. Milne,et al.  WDR5 Associates with Histone H3 Methylated at K4 and Is Essential for H3 K4 Methylation and Vertebrate Development , 2005, Cell.

[43]  A. Shilatifard,et al.  A COMPASS in the voyage of defining the role of trithorax/MLL‐containing complexes: Linking leukemogensis to covalent modifications of chromatin , 2005, Journal of cellular biochemistry.

[44]  Xiang-Jiao Yang,et al.  Multisite protein modification and intramolecular signaling , 2005, Oncogene.

[45]  S. Korsmeyer,et al.  Definitive hematopoiesis requires the mixed-lineage leukemia gene. , 2004, Developmental cell.

[46]  S. Korsmeyer,et al.  Taspase1 A Threonine Aspartase Required for Cleavage of MLL and Proper HOX Gene Expression , 2003, Cell.

[47]  J. Hess,et al.  Dimerization of MLL fusion proteins immortalizes hematopoietic cells. , 2003, Cancer cell.

[48]  G. Ehninger,et al.  Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[49]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[50]  Paul Tempst,et al.  Proteolytic Cleavage of MLL Generates a Complex of N- and C-Terminal Fragments That Confers Protein Stability and Subnuclear Localization , 2003, Molecular and Cellular Biology.

[51]  M. Cleary,et al.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. , 2002, Blood.

[52]  P. D. Dal Cin,et al.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). , 2001, The American journal of pathology.

[53]  S. Korsmeyer,et al.  MLL and CREB Bind Cooperatively to the Nuclear Coactivator CREB-Binding Protein , 2001, Molecular and Cellular Biology.

[54]  C. Pui,et al.  Biological and therapeutic aspects of infant leukemia. , 2000, Blood.

[55]  R. D. Hanson,et al.  Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[57]  R. D. Hanson,et al.  MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Komori,et al.  Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. , 1998, Blood.

[59]  Michael L. Cleary,et al.  The Oncogenic Capacity of HRX-ENL Requires the Transcriptional Transactivation Activity of ENL and the DNA Binding Motifs of HRX , 1998, Molecular and Cellular Biology.

[60]  S. Korsmeyer,et al.  Defects in yolk sac hematopoiesis in Mll-null embryos. , 1997, Blood.

[61]  D. Housman,et al.  MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[62]  F. Behm,et al.  All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. , 1997, Blood.

[63]  M. Caligiuri,et al.  ALL-1 partial duplication in acute leukemia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Caligiuri,et al.  Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.